Early Microaxial Flow Pump in Cardiogenic Shock: CRM, November 2025 Analysis Reveals Higher Mortality and Complication Risks
A recent nationwide retrospective study found that early use of microaxial flow pumps (mAFP) in patients with acute myocardial infarction-related cardiogenic shock (AMI-CS) was associated with a 2.31-fold increase in the odds of in-hospital mortality. Patients treated with these devices within 24 hours of admission also faced significantly higher risks of major bleeding and acute kidney injury requiring dialysis compared to those receiving other forms of support or delayed intervention.
These findings were published in November 2025, in Cardiovascular Revascularization Medicine.
The Clinical Complexity of Cardiogenic Shock
Cardiogenic Shock (CS), a condition where diminished cardiac output leads to life-threatening end-organ hypoperfusion, occurs in approximately 7–10% of patients following an AMI. Despite advancements like percutaneous coronary intervention (PCI) to restore blood flow, mortality rates for these patients remain as high as 40–50%. While some randomized trials have suggested survival benefits for Mechanical Circulatory Support (MCS) devices like the mAFP in highly selected populations, real-world data across broader patient groups has remained uncertain.
Study Overview
The retrospective, observational cohort study utilized the National Inpatient Sample (NIS) to analyze approximately 90,070 weighted hospitalizations between 2016 and 2021. The research focused on adult patients with AMI-CS who underwent PCI on their first day of hospital admission. The primary objective was to evaluate contemporary clinical outcomes—including in-hospital mortality and major complications—associated with the placement of a mAFP within 24 hours of admission compared to those who did not receive the device early.
The key findings from the study include:
Among the 90,070 hospitalizations analyzed, 15.5% of patients received a mAFP within 24 hours of admission.
After adjusting for demographics and comorbidities, early mAFP use was associated with significantly higher odds of in-hospital mortality (Adjusted Odds Ratio [aOR] 2.31).
Early device placement was also linked to increased rates of major bleeding (aOR 2.52) and acute kidney injury requiring dialysis (aOR 2.58).
The results were consistent across subgroups, showing similar risks for both ST-Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI) related shock.
Clinical Relevance and Refined Patient Selection
For practicing physicians, the analysis highlights that early mAFP use in real-world AMI-CS populations may not mirror the survival benefits seen in highly controlled clinical trials. The 2.31-fold increase in mortality risk underscores the necessity for long-term vigilance and refined patient selection. High rates of major bleeding and acute kidney injury suggest that the known risks of these large-bore devices must be carefully balanced against potential hemodynamic benefits. Overall, while the mAFP remains a vital tool in the cardiac arsenal, these findings reinforce that it is not universally beneficial. Providers should continue to utilize multidisciplinary shock teams and data-driven protocols to determine the optimal timing and candidacy for mechanical support on a case-by-case basis.
Reference
Desai AV, Connolly JE, Rani R, Minhas AS, Johnston P, Rahman F. Timing of microaxial flow pump in acute myocardial infarction related cardiogenic shock: A national analysis of mortality and complications. Cardiovascular Revascularization Medicine. 2026; 83: 52-58
